At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 285 enrolled
Drug / intervention
GSK573719 125mcg +3 moredrug
Likely dose
GSK573719 125mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
In Brief
A Phase 2 clinical trial evaluating GSK573719 125mcg, GSK573719 250mcg, and 2 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 285 participants across 20 sites in 4 countries.
Detailed Summary
The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesEstonia, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartDec 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedDec 14, 2009
Enrollment StartDec 15, 2009
Primary CompletionJul 4, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.6 years ago
Interventions
GSK573719 125mcgdrug
125mcg once-daily
GSK573719 250mcgdrug
250mcg once-daily
GSK573719 500mcgdrug
500mcg once-daily
Placebodrug
once-daily